Core Viewpoint - CollPlant Biotechnologies and Stratasys Ltd. have initiated a preclinical study to develop 200cc regenerative breast implants using Stratasys' 3D printing technology, aiming to provide a natural alternative to traditional implants [1][2]. Company Overview - CollPlant specializes in regenerative and aesthetic medicine, focusing on rhCollagen-based technologies for tissue regeneration and organ production [3]. - Stratasys is a leader in polymer 3D printing solutions and has modified its Origin printer for this collaboration [3]. Study Details - The preclinical study will evaluate the implants' ability to grow natural breast tissue and fully degrade over time [2][4]. - Initial results from the study are expected in the first half of 2025 [3]. Market Potential - CollPlant's innovative breast implants are positioned to capture a significant share of the $3 billion global breast implant market, offering a groundbreaking alternative for reconstructive and cosmetic procedures [5][6]. - Traditional breast augmentation procedures typically use synthetic silicone implants, which carry risks of complications [6]. Price Performance - Year-to-date, CollPlant's shares have decreased by 24.1%, contrasting with a 0.2% rise in the industry and a 17.7% increase in the S&P 500 [7].

Financial Data and Key Metrics Changes - GAAP revenues for Q2 2024 were $249,000, a significant decrease from $10.2 million in Q2 2023, primarily due to a $10 million milestone payment received in 2023 from AbbVie [14] - GAAP gross loss for Q2 2024 was $287,000, compared to a gross profit of $9.6 million in Q2 2023 [14] - GAAP net loss for Q2 2024 was $4.2 million, or $0.37 basic loss per share, compared to a net income of $5.8 million, or $0.51 basic income per share, for Q2 2023 [15] - Cash and cash equivalents as of June 30, 2024, were $18.9 million, providing a runway expected to satisfy operational requirements until at least the end of 2025 [16] Business Line Data and Key Metrics Changes - The breast implant program has progressed to testing 200 cc volume implants in preclinical studies, with the potential to address a $3 billion global breast implant market projected to grow to $6.5 billion by 2033 [6][7] - The dermal filler product, co-developed with AbbVie, is in the clinical phase, with a milestone payment of $10 million received last year [9][14] Market Data and Key Metrics Changes - The dermal filler market experienced a recent slowdown but has shown signs of recovery, evidenced by merger and acquisition activity [10] - The breast implant market is currently underserved in terms of safety and performance, with existing materials posing risks such as immunogenicity [7] Company Strategy and Development Direction - The company aims to lead in regenerative medicine through innovative collagen technology, focusing on the development of regenerative breast implants and dermal fillers [12][35] - The company has released its first environmental, social, and governance (ESG) report, emphasizing its commitment to sustainability and health [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the regenerative breast implant's potential to revolutionize aesthetic and reconstructive procedures, addressing safety concerns associated with current implants [6][8] - The company plans to advance the dermal filler program with AbbVie and generate additional safety and efficacy data for the breast implants [35] Other Important Information - The company is avoiding the use of growth factors in its scaffold technology to prevent regulatory complications, instead relying on collagen and other biomaterials [27] - The degradation of the scaffold is controlled through enzymatic degradation, hydrolysis, and oxidation, with a degradation time of six to twelve months [28] Q&A Session Summary Question: Differences between breast implants and dermal fillers - The breast implants are 3D bioprinted scaffolds that degrade and are replaced by naturally grown tissue, while dermal fillers require repeat injections and serve different purposes [18][19] Question: Key findings in the preclinical study for breast implants - The studies aim to optimize formulations, design, performance, safety, and efficacy, with a focus on fat tissue regeneration and implant degradation kinetics [21][22] Question: Next steps in the AbbVie collaboration - The dermal filler product is in clinical studies, with expectations of reaching commercialization milestones totaling $26 million, plus royalties upon approval [24] Question: Growth factors in the scaffold - The company does not use growth factors to avoid regulatory issues, relying instead on collagen's cell-binding properties to attract surrounding tissue cells [27] Question: Predictiveness of animal models - The company has developed a reliable animal model and a computational biomechanics discipline to predict scaffold behavior in humans, which will support FDA submissions [30]

COLLPLANT BIOTECHNOLOGIES LTD. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (U.S. dollars in thousands, except share and per share amounts) (Unaudited) NOTE 3 – INVENTORIES: a. Inventories as of June 30, 2024 and December 31, 2023 consisted of the following: | --- | --- | --- | --- | --- | |----------------------|-------|---------------------------------------------|--------------|----------------| | Work in progress | | June 30, 2024 \n(Unaudited) \n$ 218 | December \n$ | 31, 2023 \n173 | | Finishe ...

- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company deve ...

Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animalderived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial mark ...

REHOVOT, Israel, July 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animalderived collagen for tissue regeneration and medical aesthetics, today announced the release of its inaugural Environmental, Social and Corporate Governance (ESG) and Sustainability Report covering 2023. Commercial-size implants, CollPlant's 3D bioprinted regenerative breast implants under development Co ...

Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025 REHOVOT, Israel, June 6, 2024 /PRNewswire/ -- CollPlant B ...

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q1 2024 Results Conference Call May 29, 2024 10:00 AM ET Swayampakula Ramakanth - H.C. Wainwright Dory Kurowski In addition, any forward-looking statements made on this call represent CollPlantÂ's views only as of today, May 29, 2024 and should not be relied upon as representing the companyÂ's views as of any subsequent dates. CollPlant management specifically disclaims any obligation to update or revise any of these forward-looking statements. Good morning every ...

Additional large-animal study with commercial-size breast implants commenced in December 2023 expected to conclude in June 2024 Cash and cash equivalents balance as of March 31, 2024, was $23.2 million Conference call and webcast to discuss its financial results and corporate updates on May 29 at 10:00 a.m. Eastern Daylight Time (details herein) REHOVOT, Israel, May 29, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technol ...

Conference call information REHOVOT, Israel, May 16, 2024 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal- derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 29, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and ...